If you or a loved one developed Progressive Multifocal Leukoencephalopathy (PML) after taking Tysabri, you may be searching for answers about how this rare brain infection is linked to the medication. The medical community has long recognized the association between Tysabri and PML, and ongoing research continues to clarify the risk factors and timeline of onset. This page explains the evidence that can establish a connection between Tysabri exposure and a PML diagnosis in Illinois.
Tysabri (natalizumab) is a biologic therapy approved as monotherapy for relapsing forms of multiple sclerosis and for Crohn's disease in adults. Its use carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), a severe opportunistic brain infection caused by the JC virus. For patients in Illinois who have developed PML after Tysabri treatment, understanding the medical evidence and legal considerations—including the statute of limitations—is essential. The prescribing information for Tysabri includes a boxed warning stating that the drug "increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain that usually leads to death or severe disability" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). PML is caused by the JC virus and typically occurs only in immunocompromised patients. Three specific risk factors have been identified: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be weighed against expected benefits when initiating or continuing therapy. The clinical presentation of PML can include progressive neurological deficits such as cognitive impairment, motor weakness, gait disturbance, and visual changes. Diagnosis typically involves brain MRI showing characteristic white matter lesions and detection of JC virus DNA in cerebrospinal fluid. The FDA Adverse Event Reporting System (FAERS) data for Tysabri lists frequent adverse events including fatigue, multiple sclerosis relapse, headache, gait disturbance, memory impairment, and balance disorder (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:TYSABRI). While these reports do not directly confirm PML, they reflect the types of neurological symptoms that may overlap with or mask early PML signs. The mechanistic pathway linking Tysabri to PML involves its action as an alpha-4 integrin antagonist. By blocking lymphocyte trafficking into the central nervous system, Tysabri reduces immune surveillance, allowing latent JC virus to reactivate and cause lytic infection of oligodendrocytes. This immunosuppressive effect is dose- and duration-dependent, explaining why longer treatment increases PML risk.
The boxed warning explicitly states that Tysabri increases PML risk and that healthcare professionals should "monitor patients on TYSABRI for any new sign or symptom that may be suggestive of PML" and "withhold TYSABRI immediately at the first sign or symptom suggestive of PML" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The drug is available only through the restricted TOUCH Prescribing Program, which aims to ensure risk mitigation. However, questions may arise about whether these warnings were adequately communicated to patients and whether monitoring protocols were followed in individual cases. For patients who developed PML, the timeline between exposure and documented harm is critical. PML can occur after months to years of treatment, and symptoms may initially be subtle, leading to delayed diagnosis.
For individuals in Illinois who have been diagnosed with PML after Tysabri use, legal claims may involve product liability, failure to warn, or negligence. The statute of limitations for personal injury claims in Illinois is generally two years from the date the injury was discovered or should have been discovered. For PML, the discovery date may be when a physician confirms the diagnosis or when symptoms become clearly attributable to the drug. Given the progressive nature of PML, early symptoms such as cognitive decline or motor weakness might be misattributed to multiple sclerosis itself, potentially delaying discovery. It is important for affected patients or their families to consult with an attorney promptly to assess their specific timeline and preserve legal rights.
Tysabri carries a known risk of PML, with clear risk factors and mandated monitoring. For Illinois patients who have suffered PML, the medical evidence supports a causal link, but legal action depends on timely filing within the statute of limitations. A thorough review of the patient's treatment history, symptom onset, and diagnosis date is necessary to determine eligibility for a claim.
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
In Illinois, the statute of limitations for personal injury claims is generally two years from the date the injury was discovered or should have been discovered. For PML, the discovery date is typically when a physician confirms the diagnosis or when symptoms become clearly attributable to Tysabri. Given the progressive nature of PML, early symptoms may be misattributed to multiple sclerosis, potentially delaying discovery. It is crucial to consult an attorney promptly to assess your specific timeline.
The prescribing information for Tysabri includes a boxed warning stating that the drug increases the risk of PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Three specific risk factors have been identified: presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants. The FDA Adverse Event Reporting System also lists neurological symptoms that may overlap with PML (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:TYSABRI).
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.
Individuals with documented Tysabri exposure and a related diagnosis may request an independent, no-cost eligibility review.
Request archival records or inquire about member-exclusive transition and benefit programs.